Summary. Great attention is paid recently to studying of coronary artery disease (CAD) pathogenesis on the background of diabetes mellitus (DM). One of the pathogenetic mechanisms of atherosclerosis is generalized or chronic inflammation. In particular, the question of the role of an inflammatory component role in development of atherosclerosis in patients with DM 2 types is studied. One of new perspective markers of immune inflammation is pentraxin-3 (PTX-3). The purpose of the study –to evaluate the diagnostic value of pentraxin-3 and to study the relationship with the clinical types of coronary heart disease in patients with concomitant type 2 diabetes mellitus. Material and methods. The comprehensive examination of 110 patients with CAD was conducted. Patients were divided into groups depending on presence of DM type 2: the first group included 75 patients with stable CAD and DM type 2, the group of comparison consisted of 35 patients with CAD without DM type 2.Also patients were distributed in groups depending on the IHD clinical form: stable stenocardia, post-infarct cardiosclerosis (PIC) and diffusive cardiosclerosis. Results. In patients with CAD with concomitant DM type 2 there was defined pentraxinemia level depending on clinical types of CAD: in patients with PIC the PTX-3 level in blood serum was 5.68±0.51 ng/ml (r<0.05). In patients with stable stenocardia the PTX-3 level was 6.18±0.49 ng/ml (r<0.05). In patients with diffusive cardiosclerosis the PTX-3 level was 4.92±0.47 ng/ml (r<0.05). Pentraxinemia level in patients with CAD without DM type 2 depending on clinical types of CAD was defined as follows: in patients with PIC the PTX-3 level in blood serum constituted 3.76±0.51 ng/ml (r<0.05). In patients with stable stenocardia the PTX-3 level was 4.18±0.39 ng/ml (r<0.05). In patients with a diffusive cardiosclerosis the PTX-3 level was 2.34±0.48 ng/ml (r<0.05). Distribution of PTX-3 had same character, both in patients with DM type 2, and in patients without DM type 2. Conclusions. The diffusive cardiosclerosis was met more often in patients with coronary artery disease and the accompanying diabetes melitus type 2 (in 58.7%). The diagnostic value of pentraxin-3 is to increase the level of pentraxinemia in patients with coronary heart disease with concomitant type 2 diabetes. The pentraxin-3 levels in patients with stable stenocardia were authentically higher, than in patients with diffusive and post-infarct cardiosclerosis that is caused by more distinct activation immune inflammation.